PL1951658T3 - Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne - Google Patents
Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczneInfo
- Publication number
- PL1951658T3 PL1951658T3 PL06850148T PL06850148T PL1951658T3 PL 1951658 T3 PL1951658 T3 PL 1951658T3 PL 06850148 T PL06850148 T PL 06850148T PL 06850148 T PL06850148 T PL 06850148T PL 1951658 T3 PL1951658 T3 PL 1951658T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- receptor antagonists
- therapeutic uses
- glucagon receptor
- glucagon
- Prior art date
Links
- 229940122904 Glucagon receptor antagonist Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73778305P | 2005-11-17 | 2005-11-17 | |
| PCT/US2006/060857 WO2007123581A1 (en) | 2005-11-17 | 2006-11-14 | Glucagon receptor antagonists, preparation and therapeutic uses |
| EP06850148A EP1951658B1 (en) | 2005-11-17 | 2006-11-14 | Glucagon receptor antagonists, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1951658T3 true PL1951658T3 (pl) | 2013-02-28 |
Family
ID=38474271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06850148T PL1951658T3 (pl) | 2005-11-17 | 2006-11-14 | Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7863329B2 (pl) |
| EP (1) | EP1951658B1 (pl) |
| JP (1) | JP5198280B2 (pl) |
| CN (1) | CN101312940B (pl) |
| AU (1) | AU2006342449B2 (pl) |
| BR (1) | BRPI0618649A2 (pl) |
| CA (1) | CA2629223C (pl) |
| DK (1) | DK1951658T3 (pl) |
| ES (1) | ES2393757T3 (pl) |
| PL (1) | PL1951658T3 (pl) |
| PT (1) | PT1951658E (pl) |
| SI (1) | SI1951658T1 (pl) |
| WO (1) | WO2007123581A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1758853T3 (da) * | 2004-06-14 | 2010-04-06 | Lilly Co Eli | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser |
| WO2008098244A1 (en) | 2007-02-09 | 2008-08-14 | Metabasis Therapeutics, Inc. | Novel antagonists of the glucagon receptor |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20100074288A (ko) * | 2007-10-22 | 2010-07-01 | 오키드 리서치 레버라토리즈 리미티드 | 히스톤 디아세틸라제 억제제 |
| CN104803891B (zh) | 2008-08-13 | 2017-10-20 | 症变治疗公司 | 胰高血糖素拮抗剂 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| MX2013006768A (es) | 2010-12-23 | 2013-07-22 | Pfizer | Moduladores de receptor de glucagon. |
| US9050347B2 (en) | 2011-01-25 | 2015-06-09 | Viviabiotech, S.L. | 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor |
| ES2597972T3 (es) * | 2011-02-08 | 2017-01-24 | Pfizer Inc | Modulador del receptor de glucagón |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP3065736B1 (en) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
| JP2017519000A (ja) | 2014-06-12 | 2017-07-13 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴンアンタゴニスト |
| JP2021513564A (ja) | 2018-02-13 | 2021-05-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | グルカゴン受容体拮抗薬 |
| US11531642B2 (en) * | 2019-11-07 | 2022-12-20 | Netapp, Inc. | Synchronous object placement for information lifecycle management |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DE122006000015I1 (de) | 1993-06-21 | 2006-06-29 | Novo Nordisk As | Asp-B28-Insulinkristalle |
| SI0792290T1 (en) | 1993-09-17 | 2001-12-31 | Novo Nordisk As | Acylated insulin |
| US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
| GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
| CZ220498A3 (cs) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
| EP0923580A1 (en) | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
| AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
| NL1004346C2 (nl) | 1996-10-23 | 1998-04-24 | Dsm Nv | Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel. |
| DE69723869T2 (de) | 1996-12-31 | 2004-04-22 | Dr. Reddy's Laboratories Ltd. | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten |
| JP2001518069A (ja) | 1997-05-02 | 2001-10-09 | ドクター・レディーズ・リサーチ・ファウンデーション | 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物 |
| EP1000066A1 (en) | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| JP4391597B2 (ja) | 1997-12-02 | 2009-12-24 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体 |
| WO1999058518A2 (en) * | 1998-05-12 | 1999-11-18 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| AU6325599A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| US6353018B1 (en) | 1998-10-21 | 2002-03-05 | Novo Nordisk A/S | Compounds, their preparation and use |
| AU6325699A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU6325799A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| EP1123279A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| ES2200575T3 (es) | 1998-12-18 | 2004-03-01 | Novo Nordisk A/S | Derivados de 1,2,4-tiadiazina fusionados, su preparacion y uso. |
| WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
| CZ301366B6 (cs) | 1999-03-29 | 2010-02-03 | F. Hoffmann-La Roche Ag | 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem |
| AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| WO2000063193A1 (en) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
| TR200103851T2 (tr) | 1999-04-16 | 2002-04-22 | Dr. Reddy' S Research Foundation | Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler |
| EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU3958000A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| CA2407416C (en) | 2000-05-03 | 2006-07-18 | Paige Erin Mahaney | Alkynyl phenyl heteroaromatic glucokinase activators |
| AU5227001A (en) | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Hydantoin-containing glucokinase activators |
| EP1282611B1 (en) | 2000-05-08 | 2004-10-20 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| DK1283830T3 (da) | 2000-05-08 | 2008-08-25 | Hoffmann La Roche | Para-amin-substituerede phenylamidglucokinase-aktivatorer |
| PT1305301E (pt) | 2000-07-20 | 2005-09-30 | Hoffmann La Roche | Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1463715A1 (en) | 2001-12-03 | 2004-10-06 | Novo Nordisk A/S | Novel glucagon antagonists |
| JP2006500325A (ja) | 2002-06-27 | 2006-01-05 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
| AU2003291959A1 (en) | 2002-12-20 | 2004-07-14 | Novo Nordisk A/S | Novel glucagon antagonists |
| US7989457B2 (en) * | 2004-05-28 | 2011-08-02 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| CN101146762A (zh) | 2005-03-21 | 2008-03-19 | 默克公司 | 取代的芳基和杂芳基衍生物 |
-
2006
- 2006-11-14 DK DK06850148.5T patent/DK1951658T3/da active
- 2006-11-14 BR BRPI0618649-1A patent/BRPI0618649A2/pt not_active IP Right Cessation
- 2006-11-14 WO PCT/US2006/060857 patent/WO2007123581A1/en not_active Ceased
- 2006-11-14 SI SI200631431T patent/SI1951658T1/sl unknown
- 2006-11-14 JP JP2008541455A patent/JP5198280B2/ja not_active Expired - Fee Related
- 2006-11-14 CA CA2629223A patent/CA2629223C/en not_active Expired - Fee Related
- 2006-11-14 PL PL06850148T patent/PL1951658T3/pl unknown
- 2006-11-14 CN CN2006800431398A patent/CN101312940B/zh not_active Expired - Fee Related
- 2006-11-14 EP EP06850148A patent/EP1951658B1/en not_active Not-in-force
- 2006-11-14 AU AU2006342449A patent/AU2006342449B2/en not_active Ceased
- 2006-11-14 ES ES06850148T patent/ES2393757T3/es active Active
- 2006-11-14 PT PT06850148T patent/PT1951658E/pt unknown
- 2006-11-14 US US12/093,486 patent/US7863329B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006342449A1 (en) | 2007-11-01 |
| CN101312940B (zh) | 2012-11-14 |
| EP1951658B1 (en) | 2012-09-26 |
| EP1951658A1 (en) | 2008-08-06 |
| CA2629223C (en) | 2013-08-06 |
| CN101312940A (zh) | 2008-11-26 |
| PT1951658E (pt) | 2012-11-12 |
| AU2006342449B2 (en) | 2012-03-01 |
| JP5198280B2 (ja) | 2013-05-15 |
| US20080280982A1 (en) | 2008-11-13 |
| CA2629223A1 (en) | 2007-11-01 |
| WO2007123581A1 (en) | 2007-11-01 |
| ES2393757T3 (es) | 2012-12-27 |
| SI1951658T1 (sl) | 2012-11-30 |
| US7863329B2 (en) | 2011-01-04 |
| JP2009519228A (ja) | 2009-05-14 |
| DK1951658T3 (da) | 2012-10-15 |
| BRPI0618649A2 (pt) | 2011-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1951661T1 (sl) | Antagonisti glukagonskega receptorja priprava interapevtske uporabe | |
| SI1951658T1 (sl) | Antagonisti glukagonskega receptorja priprava interapevtska uporaba | |
| IL186601A0 (en) | Npy antagonists, preparation and use | |
| TWI346553B (en) | Chemokine receptor antagonists | |
| IL180682A0 (en) | N-hydroxamide derivatives, their preparation and use | |
| IL190686A0 (en) | Il-21 receptor antagonists | |
| IL201262A0 (en) | Gonadotropin-releasing hormone receptor antagonists and uses thereof | |
| TWI341198B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| IL179462A0 (en) | Use of the receptor gpr86 | |
| AP2006003840A0 (en) | Indole-2-carboxamidine derivatives as NMDA receptor antagonists | |
| EP1812008A4 (en) | ANTAGONISTS OF THE IL-8 RECEPTOR | |
| EP1806147A4 (en) | USE OF IMMUNOSUPPRESSIVE RECEPTOR | |
| IL190519A0 (en) | 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof | |
| IL178622A0 (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| PL1773829T3 (pl) | Pochodne aminotropanu, ich wytwarzanie oraz ich zastosowania terapeutyczne | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists | |
| SI1951659T1 (sl) | Antagonisti glukagonskega receptorja, priprava in terapevtske uporabe | |
| GB0414798D0 (en) | Receptor | |
| GB0525029D0 (en) | Receptor Antagonist | |
| ZA200605574B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| HK1111693A (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
| GB0413872D0 (en) | Receptor | |
| IL190836A0 (en) | Cxc-chemokine antagonists, their preparation and use | |
| GB0404309D0 (en) | Receptor | |
| GB0404584D0 (en) | Receptor |